WILMINGTON, Del. & CINCINNATI--(BUSINESS WIRE)--Oct 27, 2025--

Incyte (NASDAQ:INCY) and Enable Injections, Inc. (“Enable”) today announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational, first-in-class mutant calreticulin (mutCALR) selective monoclonal antibody, with Enable’s enFuse ® On-Body Delivery System.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027161257/en/

Under the terms of the agreement, Incyte will obtain a worldwide, exclusive license to use the enFuse technology with its mutCALR-targeted therapy (INCA033989) in essential thrombocythemia (ET) and myelofibrosis (MF), with the potential to expand to additional assets and indications.

See Full Page